

Declaration of Interests Register

TA Committee A

Publication Date: 08/05/2019

Topic: Abemaciclib with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID1339]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Andrew M. Wardley	Clinical expert	Direct – financial	<ul style="list-style-type: none"> Advisory work for Lilly. Site PI for MonarHER, Global trial steering committee and site PI for MonarchE. 	N/A	09/10/2018	N/A	
Professor Carlo Palmieri	Clinical expert	Direct – financial	<ul style="list-style-type: none"> Undertaken advisory boards for Pfizer, Novartis and Roche. Presented at Pfizer supported events. Investigative study part funded by Pfizer. 	N/A	18/09/2018	N/A	
				N/A	08/01/2019	N/A	

Professor Carlo Palmieri	Clinical expert	Direct – non-financial	<ul style="list-style-type: none"> Clinical study being supported by Pfizer via the NCRI-Pfizer Alliance (NEO21RS Study). Genomic Health are providing free assay as part of the same study. GTx Inc. have provided free drug and limited financial support for the EMERALD Study. Roche have supported attendance at conferences and to support educational meetings at Clatterbridge Cancer Centre. 	N/A	18/09/2018	N/A	
Mark Upton	Committee member	Direct – financial	Employee of comparator company Pfizer for two months. No shares or stock.	1999	15/12/2018	1999	
Holly Heath	Patient group representative	Direct – financial	Receives some funding from a range of pharma companies.	N/A	08/01/2019	N/A	

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>